ENHERTU supplemental New Drug Application submitted in Japan for patients with HER2 positive metastatic Solid...

Sichuan Kelun-Biotech’s SKB518 receives FDA clearance for clinical trials

Enhertu plus Pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs....

Gilead Sciences reports positive data From Phase 3 ASCENT-04/KEYNOTE-D19 study

Synthetic Design Lab emerges with $20M to advance next-generation ADCs

1st Biotherapeutics and Ligachem Biosciences partner on ADC payloads and immuno-oncology candidates